Byrski et al. [1] have chosen more decisive approach, benefiting from some favorable circumstances in Poland, e.g. well-established infrastructure for hereditary cancer diagnosis, large number of oncological patients undergoing routine DNA testing, and high impact of BRCA1 founder mutations in BC morbidity. Here, BRCA1 is linked to breast cancer.